Semaglutide vs SS-31
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Semaglutide and SS-31 (also searched as SS-31 vs Semaglutide) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Semaglutide centers on metabolic, while SS-31 leans toward healing. On indexed research, Semaglutide is ahead (Semaglutide: 57 studies, Human clinical; SS-31: 38, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Semaglutide is strongest for metabolic; SS-31 for healing.
- •Evidence: Semaglutide Human clinical (57 studies) vs SS-31 Human evidence (38).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
GLP-1 Agonist | Type 2 Diabetes and Obesity
Mitochondrial protection | Heart and neuro health
Semaglutide vs SS-31: side-by-side
| Metric | Semaglutide | SS-31 |
|---|---|---|
| Class | Metabolic | Metabolic |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human evidence |
| Studies indexed | 57 | 38 |
| Research level | FDA Approved | Preclinical |
| Strongest effect | Metabolic & appetite | Healing & recovery |
| Healing & recovery | 1.0 | 4.0▲ |
| Muscle & body comp | 1.0 | 2.0▲ |
| Metabolic & appetite | 5.0▲ | 3.0 |
| Neuro & mood | 2.0 | 4.0▲ |
| Sleep & circadian | 1.0▲ | 1.0▲ |
| Inflammation & immune | 2.0 | 3.0▲ |
| Skin & aesthetics | 4.0▲ | 1.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Semaglutide | SS-31 |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Cardiolipin binding to stabilize mitochondrial membrane |
| Route | Subcutaneous injection (oral form also available) | Subcutaneous injection |
| Half-life | ~7 days (≈165 h) | — |
| Time to peak | 1–3 days | — |
| Duration of action | Weekly dosing | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Semaglutide?
Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a hormone involved in glucose metabolism and appetite regulation. As a GLP-1 receptor agonist, semaglutide enhances insulin secretion in response to elevated blood glucose levels, suppresses glucagon secretion, and slows gastric emptying, leading to improved glycemic control. Additionally, it promotes satiety, contributing to weight loss, which has made it a focus of research for managing both type 2 diabetes and obesity.
Full Semaglutide profile, mechanism & studies →What is SS-31?
SS-31, also known as Elamipretide, is a peptide that has garnered attention for its potential role in mitochondrial protection and its implications in various health conditions, particularly those involving oxidative stress and mitochondrial dysfunction.
Full SS-31 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | SS-31 | 4.0/5 effect signal |
| Muscle | SS-31 | 2.0/5 effect signal |
| Metabolic | Semaglutide | 5.0/5 effect signal |
| Neuro | SS-31 | 4.0/5 effect signal |
| Sleep | Even | Both ~1.0/5 |
| Inflammation | SS-31 | 3.0/5 effect signal |
| Skin | Semaglutide | 4.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Semaglutide and SS-31?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Semaglutide vs SS-31: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Semaglutide has 57 approved studies indexed (Human clinical), and SS-31 has 38 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Semaglutide or SS-31 better?
It depends on your goal. Semaglutide is strongest for metabolic; SS-31 for healing. Semaglutide has more indexed studies (57). See the goal-by-goal breakdown above.
Is Semaglutide or SS-31 better for weight loss?
Semaglutide shows the stronger metabolic & appetite profile (5.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Semaglutide or SS-31 better for muscle?
SS-31 leads on the muscle & body-composition axis (2.0/5).
Which has more research, Semaglutide or SS-31?
Semaglutide has 57 approved studies indexed (Human clinical); SS-31 has 38 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Semaglutide and SS-31?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Semaglutide vs SS-31?
Semaglutide: no community-reported effects logged yet. SS-31: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Semaglutide or SS-31 FDA-approved?
Semaglutide is FDA-approved. SS-31 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is SS-31 better than Semaglutide?
For healing, SS-31 has the edge; for metabolic, Semaglutide does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.